Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
THLD > SEC Filings for THLD > Form 8-K on 15-Nov-2012All Recent SEC Filings

Show all filings for THRESHOLD PHARMACEUTICALS INC

Form 8-K for THRESHOLD PHARMACEUTICALS INC


15-Nov-2012

Other Events


Item 8.01 Other Events.

On November 15, 2012, Threshold Pharmaceuticals, Inc. issued a press release announcing updated results from a Phase 2 study of TH-302, the company's investigational hypoxia-targeted drug, in patients with soft tissue sarcoma, including additional results from patients who were administered TH-302 as single agent maintenance therapy following induction with TH-302 in combination with doxorubicin. The press release is attached as Exhibit 99.1 to this Form 8-K.

  Add THLD to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for THLD - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.